KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG
Andrea Necchi, MD, Medical Oncologist, San Raffaele Hospital and Scientific Institute, highlights the results from cohort B of the phase 2 KEYNOTE-057 trial and speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
630 Madison Ave.
Manalapan, NJ 07726
Contributors and Partners
Cancer Nursing Today
Urban Health Today
Blood Cancers Today
© 2023 Mashup Media, LLC. All rights reserved.